A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Baricitinib (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.